George Yancopoulos
Chief Scientific Officer
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer | $1,941,100 | $6,796,783 |
| 2023 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer | $1,875,415 | $7,759,830 |
| 2022 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer | $1,811,995 | $6,593,696 |
| 2021 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer Robert E. Landry (retired) | $1,767,800 | $6,398,364 |
| 2020 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. President and Chief Scientific Officer | $1,258,096 | $134,383,319 |
| 2019 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. President and Chief Scientific Officer | $1,170,500 | $20,664,135 |
| 2018 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. President and Chief Scientific Officer Robert E. Landry Executive Vice President, Finance and Chief Financial Officer | $1,130,900 | $25,381,129 |
| 2017 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. President and Chief Scientific Officer | $1,092,700 | $25,299,239 |
Earnings-call appearances
-
Regeneron Pharmaceuticals, Inc. Q4 FY2025 Earnings Call2026-01-30
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q3 FY2025 Earnings Call2025-10-28
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q2 FY2025 Earnings Call2025-08-01
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q1 FY2025 Earnings Call2025-04-29
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q4 FY2024 Earnings Call2025-01-13
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q3 FY2024 Earnings Call2024-10-31
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q2 FY2024 Earnings Call2024-08-01
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q1 FY2024 Earnings Call2024-05-02
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q4 FY2023 Earnings Call2024-01-08
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q3 FY2023 Earnings Call2023-10-05
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q2 FY2023 Earnings Call2023-08-03
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q1 FY2023 Earnings Call2023-04-10
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q4 FY2022 Earnings Call2023-02-03
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q3 FY2022 Earnings Call2022-11-03
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q2 FY2022 Earnings Call2022-08-03
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q1 FY2022 Earnings Call2022-05-04
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q4 FY2021 Earnings Call2022-02-04
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q3 FY2021 Earnings Call2021-11-04
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q2 FY2021 Earnings Call2021-08-05
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q1 FY2021 Earnings Call2021-05-06
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q4 FY2020 Earnings Call2021-01-11
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q3 FY2020 Earnings Call2020-11-05
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q2 FY2020 Earnings Call2020-08-05
Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharmaceuticals, Inc. Q1 FY2020 Earnings Call2020-05-05
Regeneron Pharmaceuticals, Inc. (REGN)